ArticleClinical & experimental optometry2019
Alpha
Article in Clinical & experimental optometry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial.Scientific reports · 2020Trial
- Amine-responsive Rhodopsin-like GPCRs in ocular pathology: mechanistic associations, candidate biomarkers, and therapeutic potential.Frontiers in physiology · 2026Review
- Resolution of Near-Work-Related Effects, Accommodation, and Binocular Vision Changes of 0.05% Atropine After 1 Year: Secondary Analysis of a Prospective Study.Ophthalmology and therapy · 2025Article
- Methylphenidate Inhibits the Development of Myopia by Altering Dopamine and Norepinephrine Reuptake.Investigative ophthalmology & visual science · 2025Article
- Topical review: Potential mechanisms of atropine for myopia control.Optometry and vision science : official publication of the American Academy of Optometry · 2025Review
- The potential of brimonidine for myopia treatment: Targeting MMP-2 to regulate choroidal thickness and control eye growth.Heliyon · 2024Article
- Brimonidine as a possible treatment for myopia.BMC ophthalmology · 2024Article
- RNA-sequencing analysis reveals the long noncoding RNA profile in the mouse myopic retina.Frontiers in genetics · 2022Article
- Insights into the mechanism by which atropine inhibits myopia: evidence against cholinergic hyperactivity and modulation of dopamine release.British journal of pharmacology · 2021Article
- Intravitreal brimonidine inhibits form-deprivation myopia in guinea pigs.Eye and vision (London, England) · 2021Article
- Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute.European journal of ophthalmology · 2021Article
- IMI Risk Factors for Myopia.Investigative ophthalmology & visual science · 2021Review
- Lens-induced myopization and intraocular pressure in young guinea pigs.BMC ophthalmology · 2020Article
- Studies on retinal mechanisms possibly related to myopia inhibition by atropine in the chicken.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Article
- Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way.Trends in pharmacological sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe putative myopia-controlling receptor is thought to be muscarinic acetylcholine receptor subtype M
methodsRight eyes of White Leghorn chicks were goggled with diffusers to induce form-deprivation myopia; left eyes were left open as controls. Goggled eyes were injected intravitreally with 20 μL of vehicle, or 2, 20, or 200 nmol of brimonidine, clonidine, guanfacine, or yohimbine, 24, 72, and 120 hours after goggle application. Alternatively, myopia was inhibited physiologically by goggle removal for two hours, and the α
resultsBrimonidine (20 and 200 nmol) and clonidine (200 nmol) effectively inhibited experimentally induced increases in negative refractive error and axial elongation. All doses of guanfacine significantly inhibited induced negative refractive error, but only 20 and 200 nmol significantly inhibited axial elongation. Yohimbine had no effect on form-deprivation myopia, but 200 nmol reduced the myopia-inhibiting effect of goggle removal.
conclusionHigh concentrations of α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.